News

BOLERO 3: Everolimus may overcome trastuzumab resistance in HER2-positive breast cancer

View on the News

An option after pertuzumab and TDM-1

BOLERO-3 has landed in a crowded field of trastuzumab-resistant clinical trials. The unique aspect of BOLERO-3 was that it did allow for prior lapatinib use, and patients were allowed to go on to study even in the fourth-line metastatic setting.

Clinically, there was no benefit for the addition of everolimus in terms of the objective response rate or clinical benefit rate. In addition – and I think this is one of the most interesting aspects of this study – there were subgroups of patients who appeared to derive less benefit from the addition of everolimus, including the estrogen receptor–positive subgroup, patients with liver involvement, and probably most intriguing, those patients who had never seen trastuzumab in the adjuvant setting.

Is there a role for mTOR inhibition in HER2-positive metastatic breast cancer? My answer is ... yes, no, maybe so.

Yes, everolimus did improve progression-free survival. The study met its primary endpoint.

No, it had little impact on other clinically meaningful outcomes, some subgroups did not derive significant benefit, and it really is too early to see an overall survival advantage.

And finally, maybe so, because it did appear to have activity in a unique study design in patients having received prior lapatinib and relapsing having had a year of adjuvant trastuzumab, which makes this study unique.

In sum, the BOLERO-3 regimen offers a potential treatment option for patients after pertuzumab and TDM-1 therapy.

Dr. Kimberly L. Blackwell is a professor at the Duke Cancer Institute in Durham, N.C. She was the invited discussant of the study. Dr. Blackwell disclosed that she is a consultant to Genentech, the maker of Perjeta and Kadcyla, and GlaxoSmithKline; she receives research funding from Novartis, the maker of Afinitor, and Roche/Genentech.


 

AT THE ASCO ANNUAL MEETING 2013

The patients in the BOLERO-3 trial were randomized evenly to daily everolimus versus daily placebo, each added to weekly trastuzumab (Herceptin) and vinorelbine.

Everolimus is currently approved by the Food and Drug Administration for use in combination with exemestane to treat advanced hormone receptor–positive, HER2-positive breast cancer in postmenopausal women. It is also approved for selected indications in other cancers.

A fourth of patients had previously received lapatinib (Tykerb). The large majority had received one or two prior lines of therapy for metastatic disease.

Median progression-free survival was 1.22 months longer with everolimus (7.00 vs 5.78 months; hazard ratio, 0.78; P = .0067).

The overall rate of response did not differ significantly between the everolimus and placebo groups (41% vs. 37%).

The everolimus arm had higher rates than the placebo group for grade 3/4 stomatitis (13% vs. 1%), fatigue (12% vs. 4%), and hematologic adverse events. But the groups were statistically indistinguishable with respect to the time to definitive deterioration of global health status.

The rate of death was 36% with everolimus and 41% with placebo, a nonsignificant difference, although longer follow-up is needed for definitive overall survival data.

The trial was sponsored by Novartis, the maker of Afinitor. Dr. O’Regan disclosed that she is a consultant to Novartis, and receives research funding from Genentech, the maker of Kadcyla and Perjeta, and Novartis.

Pages

Recommended Reading

Weekly adjuvant paclitaxel for breast cancer has less toxicity
MDedge Hematology and Oncology
ASCO 2013: Breast cancer research highlights
MDedge Hematology and Oncology
Axillary radiation halves lymphedema rate vs. ALND for breast cancer
MDedge Hematology and Oncology
Gene mutations found in 22% of African American breast cancer patients
MDedge Hematology and Oncology
How will sequestration affect American cancer care?
MDedge Hematology and Oncology
Supreme Court: Human genes cannot be patented
MDedge Hematology and Oncology
BOLERO-3: Everolimus tweaks trastuzumab-resistant metastatic breast cancer
MDedge Hematology and Oncology
Cancer health disparities and risk factors: lessons from a woman with a 20-cm chest wall mass, growing for 2 years
MDedge Hematology and Oncology
The 'Jolie effect' on BRCA risks
MDedge Hematology and Oncology
Updated guideline urges discussion of breast cancer chemoprevention
MDedge Hematology and Oncology